UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 16, 2019
Joway Health Industries Group Inc.
(Exact name of registrant specified in charter)
| Nevada | 333-108715 | 98-0221494 | ||
| (State of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
No. 19, Baowang Road, Baodi Economic Development Zone,
Tianjin, PRC 301800
(Address of principal executive offices) (Zip Code)
+(86) 22-22533666
Issuer’s Telephone Number
N/A
Former Name or Former Address, if Changed Since Last Report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Securities registered pursuant to Section 12(b) of the Act: None
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| Common Stock par value $0.001 per share | GTVI | OTCQB marketplace of OTC Markets Inc. |
Item 7.01. Regulation FD Disclosure.
On August 21, 2019, the Company issued a press release concerning the above matter. A copy of the press release is furnished herewith as Exhibit 99.1.
Item 8.01 Other Events.
On August 16, 2019, Joway Health Industries Group Inc. (the “Company”) received an inquiry from the OTC Markets concerning the recent publication of certain promotional statements and the resultant rise in the price of the Company’s common stock as traded on the OTCQB.
The Company and its management have no knowledge of why these promotional activities occurred, do not endorse such activities, and believe that certain of the statements contained in the promotional activity were inaccurate. See attached press release for additional details.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No | Description | |
| 99.1 | Press Release |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Joway Health Industries Group Inc. | ||
| By: | /s/ Jinghe Zhang | |
| Name: | Jinghe Zhang | |
| Title: | Chief Executive Officer | |
| Dated: |
August 21, 2019 | |
2
Exhibit 99.1
For Immediate Release
August 21, 2019
JOWAY HEALTH INDUSTRIES GROUP INC. RESPONDS TO PROMOTIONAL PUBLICATIONS
On August 16, 2019, Joway Health Industries Group Inc. (the “Company”) received an inquiry from the OTC Markets concerning the recent publication of three separate statements published on the websites of certain stock promoters, with a resultant rise in the price of the Company’s common stock as traded on the OTCQB under the symbol GTVI.
Set forth below are certain of the questions posed by the OTC Markets and the Company’s responses to such questions.
| 1. | Provide a summary of the Company’s explanation for the increased trading activity beginning on or about August 15th. |
Company Response: We learned about the increased trading activity beginning on or about August 15th from your email. We immediately made inquiries of our president, CEO, CFO and other third party service providers, and we did not find out anyone responsible for the promotional activity. We have no idea about the reasons for the increased trading activity.
| 2. | State if the Company has engaged any third-party providers for investor relations services, public relations services, marketing, promotion or other related services since our last request dated July 8, 2019. |
Company Response: The Company has not.
| 3. | Describe steps the Company has taken since our last request to identify who is responsible for the promotional activity. |
Company Response: We have made continued inquiries of our president, CEO, CFO and other third party service firms, but we have been unable to identify who is responsible for the promotional activity. Until now we did not receive any report about the suspicious person or the new promotional activity.
| 4. | Describe how the Company plans to address the current promotional activity |
Company Response: We will continue to make inquiries of our officers and third party service providers and advise them not to engage in any promotional activity. As we are not responsible for the current activity, we do not know how to address it.
| 5. | Describe any and all procedures undertaken by the Company to mitigate future promotional activities. |
Company Response: As noted, we will continue to monitor our officers and third party service providers and advise them not to engage in any promotional activity and to inform the Company immediately if they become aware of any such activity.
| 6. | State if any regulatory bodies, including but not limited to the Securities and Exchange Commission and FINRA, have requested information from or contacted the Company since our last request. |
Company Response: We have not received any such request or had any such contact.
In summary, the Company and its management have no knowledge of why these promotional statements were published, do not endorse such statements, and believe that certain of the statements contained in the promotional activity were inaccurate.
For further information contact:
Jessie Zhan, Financial Department
Joway Health Industries Group Inc.
Email: zhangjh@jowaygroup.com
Tel: +86 -22 -2253 3666